Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11701911 | 0.89 | TAAR1 (0.50) | TAAR1ESR1NR3C1PGRNR3C2 | |
| SCHEMBL10980509 | 0.86 | KEAP1 (0.46) | FFAR1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7332798 | 0.85 | TAAR1 (0.57) | TAAR1ESR1NR3C1PGRNR3C2 | |
| SCHEMBL6586 | 0.83 | FFAR1 (0.68) | TAAR1ESR1NR3C1PGRNR3C2 | |
| SCHEMBL5666545 | 0.81 | TAAR1 (0.53) | TAAR1ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4234560 | 0.81 | ALDH1A1 (0.60) | TAAR1ESR1NR3C1PGRNR3C2 | |
| SCHEMBL2754670 | 0.81 | TAAR1 (0.58) | TAAR1ESR1NR3C1PGRNR3C2 | |
| SCHEMBL77287 | 0.81 | EGFR (0.50) | TAAR1ESR1NR3C1PGRNR3C2 | |
| SCHEMBL9479297 | 0.80 | HDAC6 (0.65) | TAAR1FFAR1FFAR4MEN1ALDH1A1 | |
| SCHEMBL3252805 | 0.79 | PLAAT3 (0.55) | TAAR1THRATHRBFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1802630-A2 | TRITYL DERIVATIVES FOR ENHANCING MASS SPECTROMETRY | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006032893-A2 | TRITYL DERIVATIVES FOR ENHANCING MASS SPECTROMETRY | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
| US-5041442-A | Antiulcer agents | SYNTEX (U.S.A.) INC. (US) | 1991-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | F3, TBCA, GYPA | TAAR1 2196/4885ESR1 4265/4885NR3C1 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.